Soubieux Annaelle, Plante Caroline, Ouellette-Frève Johann-François, Chouinard Audrey, Bussières Jean-François
travaille à l'Unité de recherche en pratique pharmaceutique, Département de pharmacie, Centre hospitalier universitaire Sainte-Justine, Montréal (Québec). Elle est aussi candidate au D. Pharm. à l'Université Paris Descartes.
, B. Sc. Inf., travaille au Département d'hémato-oncologie, Centre hospitalier universitaire Sainte-Justine, Montréal (Québec).
Can J Hosp Pharm. 2020 Jan-Feb;73(1):27-36. Epub 2020 Feb 1.
Many strategies aim to reduce the risk of work-related exposure to hazardous drugs for health care workers; these strategies include the use of specific systems to prepare and administer these drugs.
To compare the cost of supplies used for preparing and administering one IV dose of antineoplastic in an adult health care facility in Canada between the traditional approach and one using a closed-system drug transfer device (CSTD).
This study was a cost reduction analysis conducted from the perspective of a typical university health care facility. The assessment focused only on the cost of supplies used to prepare and administer one IV dose of antineoplastic. It was not necessary to account for discounting. We developed 12 scenarios involving some of the 11 possible steps in preparing and administering one IV dose of antineoplastic.
The cost of supplies used to prepare and administer one IV dose of antineoplastic ranged between $9.89 and $22.37 per dose with the classical system, and between $12.34 and $64.19 per dose for systems involving a CSTD. The annual average extra cost of systems involving a CSTD was 1.63 to 3.15 higher than the cost with the classical system and represents extra spending of between $363 566 and $1 238 072 each year for a typical adult health care institution.
This cost reduction analysis presents original data relating to the preparation and administration of IV antineoplastics. Given the significant costs associated with preparing and administering antineoplastic drugs, decision-makers should perform a thorough analysis of costs and consequences to allow informed decisions to be made.
许多策略旨在降低医护人员工作中接触危险药物的风险；这些策略包括使用特定系统来配制和使用这些药物。
比较加拿大一家成人医疗机构中，传统方法与使用密闭式药物转移装置（CSTD）配制和使用一剂静脉注射抗肿瘤药物的耗材成本。
本研究是从一家典型大学医疗机构的角度进行的成本降低分析。评估仅关注配制和使用一剂静脉注射抗肿瘤药物的耗材成本。无需考虑贴现。我们制定了12种情景，涉及配制和使用一剂静脉注射抗肿瘤药物的11个可能步骤中的一些步骤。
传统系统配制和使用一剂静脉注射抗肿瘤药物的耗材成本为每剂9.89美元至22.37美元，而涉及CSTD的系统每剂成本为12.34美元至64.19美元。涉及CSTD的系统每年的平均额外成本比传统系统高1.63至3.15倍，对于一家典型的成人医疗机构来说，每年额外支出在363566美元至1238072美元之间。
本成本降低分析提供了与静脉注射抗肿瘤药物配制和使用相关的原始数据。鉴于配制和使用抗肿瘤药物的成本巨大，决策者应全面分析成本和后果，以便做出明智的决策。
